DARA BioSciences, Inc. (NASDAQ:DARA) an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced its support for Neuropathy Awareness Week which is being observed during the week of May 12, 2014 and sponsored in the U.S. by The Neuropathy Association (www.neuropathy.org). DARA Biosciences Inc (NASDAQ:DARA) weekly performance is -24.46%. On last trading day company shares ended up $1.05. Analysts mean target price for the company is $2.00. DARA Biosciences Inc (NASDAQ:DARA) distance from 50-day simple moving average (SMA50) is -56.60%.
Approximately 160,000 shares of MeetMe, Inc.’s (NASDAQ:MEET) common stock were sold through E*TRADE Financial Corporation on behalf of employees of the Company pursuant to pre-existing “sell to cover” elections. Proceeds of these sales were used to satisfy withholding tax obligations associated with the vesting of the shares of restricted stock of the Company held by these employees. These sales did not include any shares owned by the Company’s Chief Executive Officer or Chief Financial Officer. MeetMe Inc (NASDAQ:MEET) shares fell -8.29% in last trading session and ended the day on $1.88. Its return on assets is -11.40%. MeetMe Inc (NASDAQ:MEET) quarterly performance is -29.32%.
ChinaCache International Holdings Ltd. (Nasdaq:CCIH) reported Q1 revs of RMB230.8 million and loss of RMB.02 per share, from revs of RMB323.9 million and EPS of RMB.02 posted in the same period last year. ChinaCache Internatnl Hldgs Ltd (ADR) (NASDAQ:CCIH) shares moved down -17.11% in last trading session and was closed at $11.92, while trading in range of $11.81 – $14.87. ChinaCache Internatnl Hldgs Ltd (ADR) (NASDAQ:CCIH) year to date (YTD) performance is 33.78%.
ROI Acquisition Corp (NASDAQ:EVRY) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a report issued on Friday,American Banking & Market News reports. They currently have a $1.30 price objective on the stock.Zacks‘s target price points to a potential downside of 5.80% from the stock’s previous close. ROI Acquisition Corp (NASDAQ:EVRY) ended the last trading day at $0.939. Company weekly volatility is calculated as 20.08% and price to cash ratio as 6.49. ROI Acquisition Corp (NASDAQ:EVRY) showed a negative weekly performance of -50.58%.
Enzymotec Ltd. (NASDAQ:ENZY) a developer, manufacturer and marketer of innovative bio-active lipid ingredients, reports that it was informed that AarhusKarlshamn AB, or AAK, a Sweden-based, global producer of specialty oils that is Enzymotec’s joint venture partner in Advanced Lipids AB, submitted a claim for arbitration against the Company seeking certain declaratory relief with respect to the joint venture agreement. Enzymotec Ltd (NASDAQ:ENZY) net profit margin is 11.70% and weekly performance is -33.47%. On last trading day company shares ended up $12.90. Analysts mean target price for the company is $29.00. Enzymotec Ltd (NASDAQ:ENZY) distance from 50-day simple moving average (SMA50) is -40.85%.